Phase II gemcitabine and nab-paclitaxel for resectable pancreas cancer.

 

Trial Summary:

The effect of preoperative gemcitabine and nab-paclitaxel on the rate of surgery with complete removal of the tumour, compared with historical controls, in patients with resectable pancreas cancer.

Supported By:

Specialised Therapeutics, AGITG; NHMRC CTC

Eligibility:

Adults 18 years and over with resectable pancreatic cancer

Registration ID:

ACTRN12611000848909

Participation:

Australia

Australian Lead Group:

AGITG

Status:

Close out

Activation Date:

16/06/2012

Chairs:

Andrew Barbour and David Goldstein

Contact:

gap@ctc.usyd.edu.au